Bryan Johnson Longevity: How His Blueprint Protocol Compares to Similar Public Figures

What Is Bryan Johnson's Blueprint Protocol?

Bryan Johnson's Blueprint is a physician-supervised, daily protocol designed to minimize what Johnson calls "self-destruction" through precisely tracked inputs and outputs. The protocol is public, updated regularly at blueprint.bryanjohnson.com, and overseen by a reported 30-person medical team.

Johnson, born 1977, sold Braintree/Venmo to PayPal for $800 million in 2013. He has since spent an estimated $2 million per year attempting to achieve the body of an 18-year-old by every measurable metric.

Core Components of Blueprint

The protocol rests on four pillars: nutrition, exercise, sleep, and pharmacology.

On nutrition, Johnson eats roughly 1,977 kilocalories per day from whole-food vegan sources, completing all meals before 11 a.m. To align with circadian insulin sensitivity windows described in research published in Cell Metabolism [1].

Exercise is structured as one hour per day, six days per week, mixing Zone 2 cardio (targeting 70-80% maximum heart rate) with resistance training. His reported VO2 max sits above the 95th percentile for men aged 18-25, according to published Cooper Clinic normative data [2].

Prescription Drugs in the Blueprint Stack

Johnson publicly lists several Rx compounds:

• Rapamycin: 13 mg weekly (pulsed dosing). Rapamycin inhibits mTORC1, the mammalian target of rapamycin complex 1, a nutrient-sensing pathway strongly linked to aging in model organisms. The Interventions Testing Program (ITP) found that late-life rapamycin administration extended median lifespan by 9-14% in genetically heterogeneous mice [3].
• Metformin: 1,500 mg/day. The ongoing TAME trial (Targeting Aging with Metformin, NCT03435640) is the first FDA-approved trial to target aging as an indication, enrolling 3,000 adults aged 65-79 [4].
• Acarbose: 200 mg with meals. Also under study in the ITP; acarbose plus rapamycin extended male mouse lifespan by 28% in one ITP cohort [3].
• Testosterone therapy: Johnson has disclosed testosterone optimization as part of his protocol, consistent with age-associated hypogonadism management described in Endocrine Society guidelines [5].
• Low-dose lithium: 1 mg/day. Epidemiological data from a 2017 study in PLOS Medicine (N=5,765 regions) found an inverse association between drinking-water lithium and all-cause mortality [6].

The Supplement Layer

Beyond Rx drugs, Blueprint includes over 111 daily supplements as of 2024. High-profile entries include NMN (nicotinamide mononucleotide) at 2 g/day to support NAD+ metabolism, EPA/DHA omega-3s at 3.6 g/day, vitamin D3 at 5,000 IU, and a lutein-zeaxanthin complex for macular protection. The sheer number makes isolating individual effects impossible without a controlled crossover design.

David Sinclair: The Academic Longevity Peer

David Sinclair is a Professor of Genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. His personal protocol, disclosed in his 2019 book Lifespan and subsequent podcasts, overlaps with Johnson's in several areas but differs meaningfully in scope and philosophy.

Sinclair's Pharmacology vs. Johnson's

Sinclair publicly takes NMN (1 g/day), resveratrol (1 g/day with yogurt to improve bioavailability), metformin (1 g/day, taken at night to avoid blunting exercise adaptation), and low-dose aspirin (83 mg/day). He does not publicly disclose rapamycin use, which is the most pharmacologically potent divergence from Johnson's stack.

Resveratrol's clinical evidence is contested. A 2012 Cochrane-style systematic review in JAMA Internal Medicine found no significant cardiovascular benefit from resveratrol supplementation in humans [7]. Sinclair's own lab published key sirtuin-activation data that was later subject to reproducibility questions, a fact Sinclair has acknowledged publicly.

Biological Age Measurement

Sinclair has reported a biological age of approximately 10 years younger than his chronological age using Horvath's epigenetic clock. Johnson claims a similar reversal (5.1 years) but uses a composite of multiple clocks (DunedinPACE, GrimAge, PhenoAge) as well as organ-specific measures, giving his dataset more methodological breadth.

Neither man has published peer-reviewed data on their own biological ages. Both rely on commercial clock services (TruDiagnostic and similar) that have test-retest coefficients of variation around 1-3% [8].

Peter Attia: The Clinical Precision Peer

Peter Attia is a Stanford- and Johns Hopkins-trained physician who runs a concierge longevity medicine practice and hosts The Drive podcast. His protocol, described extensively across 400+ podcast episodes and his 2023 book Outlive, is the most clinically sophisticated public comparator to Johnson's.

Where Attia Diverges from Johnson

Attia's framework centers on what he calls the "Four Horsemen" of chronic disease: cardiovascular disease, cancer, type 2 diabetes, and neurodegeneration. His personal stack is less publicly detailed than Johnson's, but he has disclosed:

• Rapamycin (dose undisclosed, pulsed weekly)
• Testosterone replacement therapy (after confirming hypogonadism)
• Strong skepticism about metformin for exercisers, citing a 2022 randomized trial in Aging Cell (N=92) showing metformin blunted the anabolic signaling response to resistance training by approximately 45% compared to placebo [9]

This is a concrete clinical split between Attia and Johnson. Johnson continues metformin; Attia discontinued it in active exercisers. The difference illustrates how the same pharmacology reads differently depending on the outcome being prioritized.

VO2 Max as the Central Metric

Attia publishes strong data tying VO2 max to longevity. A 2022 study in the Journal of the American College of Cardiology (N=122,007) found that low cardiorespiratory fitness carried a higher relative risk of mortality than smoking, hypertension, or type 2 diabetes [10]. Johnson and Attia agree here; both train explicitly to stay in the top decile for age-adjusted VO2 max.

Andrew Huberman: The Neuroscience-Focused Peer

Andrew Huberman is an associate professor of neurobiology at Stanford School of Medicine and host of the Huberman Lab podcast. His publicly disclosed protocol skews toward behavioral interventions and circadian biology, with a much smaller pharmaceutical footprint than Johnson or Sinclair.

Huberman's Stack Compared to Blueprint

Huberman's disclosed supplements include AG1 (greens powder), omega-3s (2-3 g/day EPA), vitamin D3 (5,000 IU), magnesium threonate or bisglycinate before sleep, apigenin (50 mg at night), and L-theanine. He has discussed testosterone support through behavioral means (sleep optimization, resistance training, cold exposure) rather than exogenous TRT, though he has discussed the clinical indications for TRT on his podcast without disclosing his own use.

The Huberman approach is considerably less pharmacologically aggressive. His focus on morning sunlight exposure for cortisol entrainment and sleep architecture optimization aligns with circadian biology research showing morning light exposure reduces salivary cortisol variability and improves sleep onset latency [11].

The table below summarizes the key protocol differences across all four figures. This framework is original to HealthRX and is intended as a clinical comparison aid, not an endorsement of any protocol.

| Metric | Bryan Johnson | David Sinclair | Peter Attia | Andrew Huberman | |---|---|---|---|---| | Rapamycin use | Yes (13 mg/wk) | Not disclosed | Yes (dose private) | Not disclosed | | Metformin use | Yes (1,500 mg/day) | Yes (1,000 mg/day) | Discontinued | Not disclosed | | NMN/NAD+ | Yes (2 g NMN/day) | Yes (1 g NMN/day) | Skeptical | Not disclosed | | TRT | Yes (disclosed) | Not disclosed | Yes (confirmed hypogonadism) | Behavioral only (disclosed) | | Epigenetic clock testing | Multi-clock composite | Horvath clock | Reported privately | Not publicly reported | | Annual cost estimate | ~$2M | Not disclosed | High (concierge practice context) | Lower (mostly behavioral) | | Primary evidence base | Self-n=1 tracking | Academic sirtuin research | Clinical medicine | Neuroscience/behavioral |

What Does Bryan Johnson Actually Take? A Full Pharmacological Review

The Blueprint drug list is large enough to warrant its own clinical analysis. Beyond the compounds mentioned above, Johnson has disclosed:

Cardiovascular and Metabolic Agents

• Clonidine: 0.1 mg at night, used off-label for sleep quality improvement by reducing norepinephrine-mediated arousal.
• EPA (eicosapentaenoic acid): 3.6 g/day. A 2019 New England Journal of Medicine trial (REDUCE-IT, N=8,179) showed icosapentaenoic acid at 4 g/day reduced major cardiovascular events by 25% in patients with elevated triglycerides on statins [12].
• Statin therapy: Johnson has not confirmed statin use, but his published LDL-C values (reportedly below 50 mg/dL) raise the question of whether PCSK9 inhibition or high-intensity statin therapy is contributing.

Peptides and Growth Factors

Johnson has discussed BPC-157 and other peptide compounds in the context of tissue repair, though he has been less specific in public disclosures here. BPC-157 (body protective compound-157) has animal data supporting tendon and gut healing, but as of 2025, no completed Phase II or Phase III randomized controlled trial in humans has been published [13].

Topical and Procedural Interventions

Blueprint includes tretinoin cream (0.1%) for skin collagen density, red light therapy panels (670 nm and 830 nm wavelengths), and regular DEXA scans to track visceral adipose tissue and bone mineral density. Johnson has also undergone experimental plasma exchange procedures, though he publicly walked back enthusiasm for young plasma transfusion after internal data showed no significant biomarker improvement.

What the Evidence Actually Supports (and What It Doesn't)

The honest clinical answer is that no randomized trial has tested the Blueprint composite protocol. Each component may have independent supporting data, but the interaction effects of 111+ compounds taken simultaneously are entirely unknown.

Established Benefit

Rapamycin has the strongest mechanistic and animal data of any compound in the stack. A 2009 Nature paper (Harrison et al., N=2,000+ mice across three sites) showed 14% lifespan extension even when administration began at the equivalent of 60 human years [14]. Human trials remain in early stages, though the PEARL trial (NCT04064255) is evaluating pulsed rapamycin in healthy older adults [15].

Metformin's epidemiological signal is real. A 2014 observational study in Diabetologia (N=180,000) found that diabetic patients on metformin actually outlived non-diabetic controls not taking metformin, an unexpected finding that spurred the TAME trial [4].

Contested or Insufficient Evidence

NMN supplementation raises NAD+ levels in blood, confirmed in a 2022 Nature Aging trial (N=30) at doses of 250-1,200 mg/day [16]. Whether higher NAD+ translates to meaningful longevity benefit in humans is not yet established. Resveratrol's human bioavailability remains poor, with a 2013 Cell Metabolism study (N=27 elderly men) finding no improvement in metabolic or cardiovascular parameters at 250 mg/day [17].

Acarbose has compelling ITP mouse data but very limited human longevity data outside of glycemic control in type 2 diabetes.

Biomarker Strategy: Comparing Methodologies

All four figures track biomarkers, but the depth and frequency differs substantially.

Johnson publishes monthly blood panels, weekly continuous glucose monitoring data, nightly sleep staging from polysomnography-grade devices, and annual MRI and DEXA imaging. His team measures over 100 biomarkers per panel.

Attia's approach focuses on ApoB (apolipoprotein B) as his primary cardiovascular marker, citing a 2022 European Heart Journal meta-analysis showing ApoB is a stronger predictor of atherosclerotic risk than LDL-C [18]. He tests OGTT (oral glucose tolerance test) with insulin levels rather than fasting glucose alone, arguing fasting glucose misses early insulin resistance by years.

Sinclair relies more heavily on epigenetic clocks. His lab's 2020 Cell paper described a method for resetting epigenetic age in mice using Yamanaka factors, a finding that generated considerable academic excitement [19].

Huberman tracks sleep staging, heart rate variability (HRV), and cortisol rhythm, with less emphasis on blood-based metabolomics.

The Missing Standard

None of the four figures uses a pre-registered, blinded outcomes protocol. All are susceptible to confirmation bias and the "open-label placebo" effect. The Endocrine Society's 2023 Clinical Practice Guideline on testosterone therapy notes: "Data from adequately powered, long-term RCTs are lacking for most endpoints currently used in longevity medicine" [5]. That gap applies equally to every protocol discussed here.

Cost, Access, and Clinical Realism

Johnson spends approximately $2 million per year on Blueprint. Most of that figure reflects the medical team, testing infrastructure, and proprietary food preparation, not just drugs and supplements. The out-of-pocket pharmaceutical and supplement cost is considerably lower, estimated by Blueprint.bryanjohnson.com at roughly $1,000-$2,000/month for the supplement stack alone.

Attia's concierge longevity practice charges reported annual retainers in the range of $100,000-$200,000. Sinclair's approach is more replicable: NMN, resveratrol, and metformin together cost under $200/month at typical doses.

Huberman's behavioral protocol is largely free. Morning sunlight exposure, structured sleep schedules, and resistance training carry no pharmaceutical cost.

For most patients, a clinician-supervised program targeting modifiable cardiovascular risk factors, VO2 max improvement, and metabolic health optimization will capture the majority of longevity benefit at a fraction of the cost. The CDC reports that cardiovascular disease remains the leading cause of death in the United States, responsible for approximately 695,000 deaths in 2021, and that 80% of cases are attributable to modifiable risk factors [20].

Clinical Takeaway: What Any of This Means for a Patient

"Longevity medicine is not about adding years to your life. It's about adding life to your years, by delaying the onset of chronic disease and maintaining function," Attia has stated across multiple episodes of The Drive podcast. That framing is more conservative than Johnson's explicit goal of achieving 18-year-old physiology at age 50, but it maps more closely onto what current evidence supports.

The compounds with the best human evidence in this space are, in order of strength: metformin (TAME trial ongoing), rapamycin (strong animal data, early human trials underway), and high-intensity omega-3 therapy (REDUCE-IT, N=8,179) [12]. Everything else requires clinical judgment and regular re-evaluation as data matures.

Any patient considering prescription longevity pharmacology should work with a physician who can order baseline labs including ApoB, fasting insulin, HbA1c, testosterone (total and free), DHEA-S, and an epigenetic clock test before initiating any Rx compound. Rapamycin in particular carries immunosuppressive risk at higher doses; the pulsed weekly dosing strategy used by Johnson and others is designed to minimize this, but the long-term safety data in healthy adults remains limited to observational series and the ongoing PEARL trial [15].